Profil
Mr. Jackson joined AEGON Capital Management Inc. in 1994.
Before joining AEGON, Mr. Jackson managed equity and small-cap equity funds at Colonia Life.
Mr. Jackson earned his Chartered Financial Analyst (CFA) designation in 1991 and is a member of the Toronto Society of Financial Analysts (TSFA) and the Association for Investment Management and Research (AIMR).
Ehemalige bekannte Positionen von Mark Jackson
| Unternehmen | Position | Ende |
|---|---|---|
AEGON Capital Management, Inc.
AEGON Capital Management, Inc. Investment ManagersFinance AEGON Capital Management's focus is to provide exceptional income and capital preservation solutions for their clients. The firm seeks to add value through their proprietary, bottom-up research that applies a prudent, disciplined and repeatable investment process. Equity and fixed income portfolios are built from the bottom-up based on thorough fundamental analysis. Rigorous internal research and modeling ensures that each investment decision is supported by objective information. The firm's hands-on research is over-laid with a top-down macro view supplemented by weekly team meetings in which portfolio positions are reviewed, debated and challenged in relation to their price targets and investment theses. AEGON builds focused, high-conviction portfolios with only 40 to 50 their best ideas making it into the portfolio. This leads to a relatively high concentration with the top ten holdings accounting for about 40% of total assets. They also have a strict upside and downside discipline: stocks are placed under formal review if they fall 10% and must offer compelling upside for purchase. For their income and yield portfolios, AEGON seeks to generate sustainable income and yield within equity portfolios. Their investment approach involves careful analysis of the TSX and S&P500 universe of companies to identify sustainable dividend payers, cutters and risers. When constructing equity income portfolios, AEGON is particularly interested in these high-quality dividend offerings that offer sustainable and growing yields. | Direktor der Forschung - Eigenkapital | 01.10.2010 |
NeoClone Biotechnology International LLC
NeoClone Biotechnology International LLC BiotechnologyHealth Technology Engages in the production and supply of monoclonal antibody products | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
AEGON Capital Management, Inc.
AEGON Capital Management, Inc. Investment ManagersFinance AEGON Capital Management's focus is to provide exceptional income and capital preservation solutions for their clients. The firm seeks to add value through their proprietary, bottom-up research that applies a prudent, disciplined and repeatable investment process. Equity and fixed income portfolios are built from the bottom-up based on thorough fundamental analysis. Rigorous internal research and modeling ensures that each investment decision is supported by objective information. The firm's hands-on research is over-laid with a top-down macro view supplemented by weekly team meetings in which portfolio positions are reviewed, debated and challenged in relation to their price targets and investment theses. AEGON builds focused, high-conviction portfolios with only 40 to 50 their best ideas making it into the portfolio. This leads to a relatively high concentration with the top ten holdings accounting for about 40% of total assets. They also have a strict upside and downside discipline: stocks are placed under formal review if they fall 10% and must offer compelling upside for purchase. For their income and yield portfolios, AEGON seeks to generate sustainable income and yield within equity portfolios. Their investment approach involves careful analysis of the TSX and S&P500 universe of companies to identify sustainable dividend payers, cutters and risers. When constructing equity income portfolios, AEGON is particularly interested in these high-quality dividend offerings that offer sustainable and growing yields. | Finance |
NeoClone Biotechnology International LLC
NeoClone Biotechnology International LLC BiotechnologyHealth Technology Engages in the production and supply of monoclonal antibody products | Health Technology |
















